NICE approves first treatment for obstructive HCM for NHS use
The National Institute for Health and Care Excellence (NICE) has announced that it has approved mavacamten (Camzyos) for the treatment of obstructive hypertrophic cardiomyopathy (HCM) for use on the NHS.
The drug, developed by Bristol-Myers Squibb, is intended to be used as an addition to standard of care treatment for obstructive HCM, potentially avoiding or postponing a patient’s need for invasive surgery.
Obstructive HCM is a chronic disease with more than 50% of cases being caused by an inherited genetic mutation, characterised by excessive heart muscle contractions causing it to thicken and stiffen. This means the heart may not be able to pump enough blood around the body.
Symptoms often include tiredness, dizziness, shortness of breath, chest pain and palpitations. […]
The post NICE approves first treatment for obstructive HCM for NHS use appeared first on Pharmafile.
